PCA3 and TMPRSS2-ERG: Promising biomarkers in prostate cancer diagnosis

Cancers

Volumn 2, Issue 3, 2010, Pages 1432-1440

  Salagierski, Maciej ^a,b   Schalken, Jack A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Diagnosis; Marker; Molecular; PCA3; Prostate cancer; TMPRSS2:ERG

Indexed keywords

DIAGNOSTIC ACCURACY; DISEASE MARKER; GENE FUSION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE SEQUENCE; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; PCA3 GENE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; TMPRSS2 ERG GENE; TUMOR GENE;

EID: 79952265387     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2031432     Document Type: Review

References (31)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71-96.
2. Roobol, M.J.; Zappa, M.; Maattanen, L.; Ciatto, S. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate 2007, 67, 439-446.
3. Parekh, D.J.; Ankerst, D.P.; Troyer, D.; Srivastava, S.; Thompson, I.M. Biomarkers for prostate cancer detection. J. Urol. 2007, 178, 2252-2259.
4. Bussemakers, M.J.; van Bokhoven, A.; Verhaegh, G.W.; Smit, F.P.; Karthaus, H.F.; Schalken, J.A.; Debruyne, F.M.; Ru, N.; Isaacs, W.B. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999, 59, 5975-5979.
5. Clarke, R.A.; Zhao, Z.; Guo, A.Y.; Roper, K.; Teng, L.; Fang, Z.M.; Samaratunga, H.; Lavin, M.F.; Gardiner, R.A. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS ONE 2009, 4, e4995.
6. Hessels, D.; Klein Gunnewiek, J.M.; van Oort, I.; Karthaus, H.F.; van Leenders, G.J.; van Balken, B.; Kiemeney, L.A.; Witjes, J.A.; Schalken, J.A. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 2003, 44, 8-15.
7. Schalken, J.A.; Hessels, D.; Verhaegh, G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 2003, 62, 34-43.
8. Deras, I.L.; Aubin, S.M.; Blase, A.; Day, J.R.; Koo, S.; Partin, A.W.; Ellis, W.J.; Marks, L.S.; Fradet, Y.; Rittenhouse, H.; Groskopf, J. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J. Urol. 2008, 179, 1587-1592.
9. van Gils, M.P.; Hessels, D.; van Hooij, O.; Jannink, S.A.; Peelen, W.P.; Hanssen, S.L.; Witjes, J.A.; Cornel, E.B.; Karthaus, H.F.; Smits, G.A.; Dijkman, G.A.; Mulders, P.F.; Schalken, J.A. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin. Cancer Res. 2007, 13, 939-943.
10. Haese, A.; de la Taille, A.; van Poppel, H.; Marberger, M.; Stenzl, A.; Mulders, P.F.; Huland, H.; Abbou, C.C.; Remzi, M.; Tinzl, M.; Feyerabend, S.; Stillebroer, A.B.; van Gils, M.P.; Schalken, J.A. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur. Urol. 2008, 54, 1081-1088.
11. Hessels, D.; van Gils, M.P.; van Hooij, O.; Jannink, S.A.; Witjes, J.A.; Verhaegh, G.W.; Schalken, J.A. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010, 70, 10-16.
12. van Gils, M.P.; Hessels, D.; Hulsbergen-van de Kaa, C.A.; Witjes, J.A.; Jansen, C.F.; Mulders, P.F.; Rittenhouse, H.G.; Schalken, J.A. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008, 68, 1215-1222.
13. Salagierski, M.; Verhaegh, G.W, Jannink, S.A.; Smit, F.P.; Hessels, D.; Schalken, J.A. Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. Prostate 2010, 70, 70-78.
14. Nakanishi, H.; Groskopf, J.; Fritsche, H.A.; Bhadkamkar, V.; Blase, A.; Kumar, S.V.; Davis, J.W.; Troncoso, P.; Rittenhouse, H.; Babaian, R.J. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J. Urol. 2008, 179, 1804-1809.
15. Marks, L.S.; Fradet, Y.; Deras, I.L.; Blase, A.; Mathis, J.; Aubin, S.M.; Cancio, A.T.; Desaulniers, M.; Ellis, W.J.; Rittenhouse, H.; Groskopf, J. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007, 69, 532-535.
16. Whitman, E.J.; Groskopf, J.; Ali, A., Chen, Y.; Blase, A.; Furusato, B.; Petrovics, G.; Ibrahim, M.; Elsamanoudi, S.; Cullen, J. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J. Urol. 2008, 180, 1975-1978.
17. Popa, I.; Fradet, Y.; Beaudry, G.; Hovington, H.; Beaudry, G.; Tetu B. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod. Pathol. 2007, 20, 1121-1127.
18. Mitelman, F.; Johansson, B.; Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 2007, 7, 233-245.
19. Demichelis, F.; Fall, K.; Perner, S.; Andren, O.; Schmidt, F.; Setlur, S.R.; Hoshida, Y.; Mosquera, J.M.; Pawitan, Y.; Lee, C.; Adami, H.O.; Mucci, L.A.; Kantoff, P.W.; Andersson, S.O.; Chinnaiyan, A.M.; Johansson, J.E.; Rubin, M.A. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007, 26, 4596-4599.
20. Perner, S.; Demichelis, F.; Beroukhim, R.; Schmidt, F.H.; Mosquera, J.M.; Setlur, S.; Tchinda, J.; Tomlins, S.A.; Hofer, M.D.; Pienta, K.G.; Kuefer, R.; Vessella, R.; Sun, X.W.; Meyerson, M.; Lee, C.; Sellers, W.R.; Chinnaiyan, A.M.; Rubin M.A. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006, 66, 8337-8341.
21. Perner, S.; Mosquera, J.M.; Demichelis, F.; Hofer, M.D.; Paris, P.L.; Simko, J.; Collins, C.; Bismar, T.A.; Chinnaiyan, A.M.; De Marzo, A.M.; Rubin, M.A. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 2007, 31, 882-888.
22. Hessels, D.; Smit, F.P.; Verhaegh, G.W.; Witjes, J.A.; Cornel, E.B.; Schalken, J.A. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 2007, 13, 5103-5108.
23. Morris, D.S.; Tomlins, S.A.; Montie, J.E.; Chinnaiyan, A.M. The discovery and application of gene fusions in prostate cancer. BJU Int. 2008, 102, 276-282.
24. Barry, M.; Perner, S.; Demichelis, F.; Rubin, M.A. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007, 70, 630-633.
25. Demichelis, F.; Fall, K.; Perner, S.; Andren, O.; Schmidt, F.; Setlur, S.R.; Hoshida, Y.; Mosquera, J.M.; Pawitan, Y.; Lee, C.; Adami, H.O.; Mucci, L.A.; Kantoff, P.W.; Andersson, S.O.; Chinnaiyan, A.M.; Johansson, J.E.; Rubin, M.A. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Urol. Oncol. 2007, 25, 448-449.
26. Gopalan, A.; Leversha, M.A.; Satagopan, J.M.; Zhou, Q.; Al-Ahmadie, H.A; Fine, S.W.; Eastham, J.A.; Scardino, P.T.; Scher, H.I.; Tickoo, S.K.; Reuter, V.E.; Gerald, W.L. TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy. Cancer Res. 2009, 69, 1400-1406.
27. Rubio-Briones, J.; Fernández-Serra, A.; Calatrava, A.; García-Casado, Z.; Rubio, L.; Bonillo, M.A.; Iborra, I.; Solsona, E.; López-Guerrero, J.A. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J. Urol. 2010, 183, 2054-2061.
28. Clark, J.P.; Munson, K.W.; Gu, J.W.; Lamparska-Kupsik, K.; Chan, K.G.; Yoshida, J.S.; Kawachi, M.H.; Crocitto, L.E.; Wilson, T.G.; Feng, Z. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. Clin. Chem. 2008, 54, 2007-2017.
29. Laxman, B.; Morris, D.S.; Yu, J.; Siddiqui, J.; Cao, J.; Mehra, R.; Lonigro, R.J.; Tsodikov, A.; Wei, J.T.; Tomlins, S.A.; Chinnaiyan, A.M. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 2008, 68, 645-649.
30. Petrovics, G.; Liu, A.; Shaheduzzaman, S.; Furusato, B.; Sun, C.; Chen, Y.; Nau, M.; Ravindranath, L.; Chen, Y.; Dobi, A.; Srikantan, V.; Sesterhenn, I.A.; McLeod, D.G.; Vahey, M.; Moul, J.W.; Srivastava, S. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005, 24, 3847-3852.
31. Risk, M.C.; Lin, D.W. New and novel markers for prostate cancer detection. Curr. Urol. Rep. 2009, 10, 179-186.